Alexandria Co. For Pharmaceuticals & Chemical Industries

CASE:AXPH Stock Report

Market Cap: ج.م1.1b

Alexandria For Pharmaceuticals & Chemical Industries Valuation

Is AXPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AXPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AXPH (EGP226) is trading above our estimate of fair value (EGP76.35)

Significantly Below Fair Value: AXPH is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AXPH?

Other financial metrics that can be useful for relative valuation.

AXPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.6x
Enterprise Value/EBITDA4.6x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does AXPH's PE Ratio compare to its peers?

The above table shows the PE ratio for AXPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average8.3x
OCPH October PharmaE
8xn/aج.م1.2b
CPCI Kahira Pharmaceuticals & Chemical Industries
8.9xn/aج.م1.0b
NIPH EI- Nile for Pharmaceuticals and Chemical Industries
8.6xn/aج.م811.6m
ADCI Arab Drug
7.6xn/aج.م565.1m
AXPH Alexandria For Pharmaceuticals & Chemical Industries
7.5xn/aج.م1.1b

Price-To-Earnings vs Peers: AXPH is good value based on its Price-To-Earnings Ratio (7.5x) compared to the peer average (8.3x).


Price to Earnings Ratio vs Industry

How does AXPH's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.8%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.8%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: AXPH is good value based on its Price-To-Earnings Ratio (7.5x) compared to the Global Pharmaceuticals industry average (24.1x).


Price to Earnings Ratio vs Fair Ratio

What is AXPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AXPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AXPH's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.